Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

BACKGROUND: Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the firs...

Full description

Bibliographic Details
Main Authors: Oluf Dimitri Røe, Adam Szulkin, Endre Anderssen, Arnar Flatberg, Helmut Sandeck, Tore Amundsen, Sten Even Erlandsen, Katalin Dobra, Stein Harald Sundstrøm
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3414492?pdf=render

Internet

http://europepmc.org/articles/PMC3414492?pdf=render

Similar Items